Europe Approves Merck's Cancer Drug For Two Indications
On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...
Medscape1h
Gene Panel Predicts Radiation Response in Prostate Cancer
The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.
PMLiVE5m
Merck’s Welireg granted EC approval for von Hippel-Lindau disease and kidney cancer
Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the ...
The American Journal of Managed Care22h
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...
Nanozyme targets hypoxic lesions to enhance radiosensitivity in nasopharyngeal carcinoma
A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness ...
PharmiWeb2h
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral ...
BioSpace22h
Arcus Challenges Merck in Kidney Cancer with Early Data
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
Armed robbery in Revesby6d
Nanozyme Boosts Radiosensitivity in Nasopharyngeal Cancer
A collaborative study, published on January 21 on Nature Communications, presents a novel strategy to improve the ...
FierceBiotech1d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Cure Today5d
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan
Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the ...